Liposarcoma is a malignant tumor that develops from adipose tissue and can affect various parts of the body, including the extremities, trunk, and internal organs. The tumor is caused by abnormal proliferative changes in fat cells, which leads to the formation of complex and aggressive non-septic masses. Liposarcoma is manifested by a variety of subtypes, each of which has specific morphological characteristics and prognostic indicators. This pathology requires an interdisciplinary approach to diagnosis and treatment, including surgical, radiotherapeutic, and pharmacological methods.
History of the disease and interesting historical facts
The history of liposarcoma research dates back to the late 19th century, when doctors began to classify tumor diseases, including sarcomas. In 1875, Swiss pathologist Rudolf Virchow first described malignant neoplasms from fat cells. In the 1930s, the research of Professor Alfred Lesser led to further deepening of knowledge about the types of liposarcoma. Since then, the various subtypes of liposarcoma have been detailed, which has contributed to more effective treatment of the disease. Various theories about the pathogenesis of liposarcoma are actively discussed in scientific circles, which leads to the perception of this disease as one of the most difficult tasks of modern oncological analysis.
Epidemiology
Liposarcoma is relatively rare, accounting for about 1% of all malignant tumors. According to various studies, the incidence is approximately 2-3 cases per 1 million people per year. According to statistics, the disease is most often diagnosed in adults aged 50-65 years, and men suffer from it more often than women. Some researchers note an increase in the incidence in recent decades, which is associated with lifestyle changes that lead to environmental factors, as well as taking into account more regular screening and diagnostics.
Genetic predisposition to this disease
Studies show that certain genetic changes support the development of liposarcoma. In particular, mutations have been found in the TP53 and MDM2 genes, which are key targets for the initiation of malignant growth. In addition, chromosomal aberrations, such as chromosome 12 excess, have become important markers not only for diagnosis but also for prognosis of the disease. In recent years, active attention has been paid to genomic profiling, which opens up new horizons for the development of targeted therapies.
Risk factors for the development of this disease
Factors that contribute to the development of liposarcoma include both physical and chemical exposures. Possible risk factors include:
- Soft tissue injuries that can lead to cell mutations
- Exposure to radiation, such as the effects of radiation treatment for other tumors
- Chemical carcinogens such as asbestos and some industrial solvents
- Certain inherited syndromes, such as Li-Fraumenni syndrome and neurofibromatosis type 1, which increase the risk of developing sarcomas
- Age over 50 years
Diagnosis of this disease
The main goal of diagnosing liposarcoma is to detect the disease early and determine its subtype. The main symptoms can vary, but most often include:
- Painless swellings that can grow in size
- Symptoms of compression of surrounding structures, such as pain, numbness, or increased circumference of the limb
Laboratory tests such as complete blood count and biochemical markers may be useful in assessing the patient's overall condition, but specific diagnostic results require imaging.
Radiologic tests, including ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT), are used to identify the size and location of the tumor. A biopsy is often necessary to confirm the diagnosis and determine the tumor subtype. Differential diagnosis includes exclusion of other tumors and soft tissue diseases such as fibrosarcoma or desmoid tumor.
Treatment
Treatment for liposarcoma is based on the stage of the disease and its subtype. General treatment for common forms includes:
- Surgical intervention is the main method aimed at complete removal of the tumor.
- Radiotherapy can be used as a preliminary measure before surgery or after to reduce recurrence.
- Chemotherapy is often used in the metastatic form or in combination with surgery.
Surgical treatment typically involves tissue resection with healthy margins, which significantly reduces the risk of recurrence. The use of targeted drugs, such as dacarbacine, can be part of a comprehensive approach for various forms of sarcoma.
List of medications used to treat this disease
Among the drugs used to treat liposarcoma are:
- Dacarbazine
- Epirubicin
- Topotecan
- Ifosfamide
- Mitomycin C
Disease monitoring
Monitoring of patients with liposarcoma is important to detect recurrence. Control steps should include:
- Regular check-ups with imaging after surgery and therapy
- Repeat biopsies if recurrence is suspected
- Laboratory tests to assess general condition
The prognosis for patients can vary depending on the subtype and stage of the disease. Complications can include tumor spread and disease progression, making early diagnosis and active monitoring vital.
Age-related features of the disease
Age plays a significant role in the manifestation of liposarcoma. In childhood and young age, the tumor usually has a more favorable prognosis, which is typical for more aggressive forms in later life. In older people, liposarcoma can spread widely, which is associated with other concomitant diseases and a general decrease in the body's resistance.
Questions and Answers
- What are the main symptoms of liposarcoma?
The main symptoms include painless swelling, possible compression of surrounding structures with the development of pain or numbness. - How is liposarcoma diagnosed?
Diagnosis is based on imaging techniques, biopsy and tests, which help confirm the type of tumor. - Which treatment is most effective?
The most effective method is radical surgery followed by supportive therapy if necessary. - What are the risk factors for developing liposarcoma?
Risk factors include trauma, radiation, chemical carcinogens, and hereditary syndromes. - What are the morbidity statistics?
Liposarcoma is a rare disease, occurring in approximately 2-3 per 1 million people per year.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov recommends regular medical checkups and paying attention to changes in the body. He emphasizes the importance of promptly contacting a specialist if any suspicious formations are present. He also advises maintaining a healthy lifestyle and avoiding the known carcinogens mentioned above to reduce the risk of developing the disease. “Your health is in your hands,” he concludes.
